Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Remedy Taking a hit why? -- Ignore unavailable to you. Want to Upgrade?

To: Mo Chips who wrote (472)	3/2/1998 3:51:00 PM
From: Shege Dambanza	Respond to of 763

Why would it?

To: Mo Chips who wrote (472)	3/2/1998 3:53:00 PM
From: KJSwoops	Read Replies (1) \| Respond to of 763

Very little, if at all. The gap between the internal help desk and external customer management markets is widening every day. Remedy focuses on the former, SCOP/SEBL on the latter. Scopus, who has opportunistically sold a help desk here or there, really says it's not in this business. The primary competition of SCOP/SEBL is Clarify, Vantive, Baan/Aurum, Quintus, etc. The competition for Remedy is Software Artistry/Tivoli, Peregrine, McAfee, etc. Bottom line, should have very little impact if any.